XOR-Labs Toronto (XOR) a spin-oXOR-Labs Toronto (XOR) a spin-off from Toronto General Hospital at University Health Network today announced the closing of another financing through a private placement, led by…
MaRS Innovation was highlighted in the Networks of Centres of Excellence (NCE) newsletter on Wednesday, June 22. The article is titled, "MaRS Innovation revolutionizes approach to commercialization, " and discusses…
Agreement signed as part of Ontario's life sciences trade mission to Israel TEL AVIV and TORONTO (May 16, 2016) – BioLineRx Ltd. a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising…
TORONTO (May 11, 2016) – Johnson & Johnson Innovation LLC, today announced the opening of JLABS @ Toronto, a new 40,000-square-foot life sciences incubator, providing entrepreneurs shared lab space and…
Montreal-based venture capital fund and entrepreneurship program brings over $20 million in funding and deep expertise in consumer electronics to MI members; first deal in speech recognition TORONTO and MONTREAL,…
Canadian innovation will give patients affordable, non-invasive, accurate test for cancer or infectious diseases; R&D team to remain in Toronto discovery district TORONTO and SAN FRANCISCO (May 3, 2016) —…
Applications for next MSc PoP granting round being accepted until February 25, 2016 TORONTO (January 26, 2016) — Nine Ontario-based medical research projects built on great science with potential for…
TORONTO and VANCOUVER, CANADA (January 12, 2016) — A novel drug therapy to reduce the severity and frequency of hypoglycemic (low blood sugar) episodes in people with diabetes is being…
TORONTO, ON (September 30, 2015) — Encycle Therapeutics, Inc., a University of Toronto spin-off company created in partnership with MaRS Innovation, announced today that it has completed a $2.85 million (CAD) financing led by Takeda Pharmaceutical Company Ltd. through its venture capital arm, Takeda Ventures, Inc., with Accel-Rx Health Sciences Accelerator, BDC Capital and MaRS Investment Accelerator Fund.
The funding will support ongoing development of Encycle’s unique nacellin platform chemistry and advance the company’s pipeline of novel therapeutics. It will also allow the company to build on research collaborations with several pharmaceutical companies and ultimately position it for a series A transaction and/or additional strategic partnerships.
“Our proprietary chemistry has the potential to unlock myriad therapeutic avenues, including via intracellular protein-protein interactions that cannot be targeted with conventional therapeutics,” said Dr. Jeffrey Coull, president and CEO of Encycle Therapeutics; upon the closing, Coull joined Encycle’s board of directions. “This funding is critical to enable the company to further explore the vast potential of our technology and to de-risk it to the extent that major transactions will be enabled.”
“Our goal is to make an impact on patients’ lives by turning science and technology into life-changing medicines. We are enthusiastic about Encycle’s technology and its potential in the context of ‘undruggable’ proteins,” said Dr. Ilan Zipkin, senior investment director at Takeda.
“Encycle’s growing momentum reflects MaRS Innovation’s efforts to shift the Canadian paradigm for technology transfer,” said Dr. Raphael Hofstein, chairman of the Encycle Therapeutics Board of Directors and president and CEO of MaRS Innovation. “This company began with promising research in Dr. Andrei Yudin’s laboratory at the University of Toronto. With crucial support from many players along the Ontario-Quebec life sciences corridor, MaRS Innovation collaborated with him to package and protect the technology, launch the company and hire experienced management. The success of this funding round bodes well for its future growth and success.”
MaRS Innovation’s “model solves the two weakest points in tech transfer: the lack of dealflow and the ability to match public funding,” writes Thierry Heles in, “MaRS Innovation: A Unique Model for Tech Transfer,” for Global University Venturing.
This feature was also covered in Techopia.
The article, which includes an interview with Dr. Rafi Hofstein, president and CEO of MaRS Innovation, was published September 14, 2015.
Here’s an excerpt exploring the range of MI’s portfolio and Hofstein’s strategy for addressing technologies emerging in new areas:
In the beginning, Mars received primarily discoveries in the medical sector, but the balance has since shifted to 60% medically-oriented research and 40% for other areas. The medically-oriented discoveries, Hofstein elaborated, are a diverse set of technologies and include everything from drug development and molecular diagnostics to medical devices and healthcare IT.
The remaining 40% meanwhile cover “a smörgåsbord all the way from alternative energies and solar energy, and water reclamation to all sorts of mobile apps”.
MaRS Centre, West Tower
661 University Avenue, Suite 465
Toronto, ON M5G 1M1
info@tiap.ca